We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04410991
Recruitment Status : Active, not recruiting
First Posted : June 1, 2020
Last Update Posted : August 8, 2022
Sponsor:
Information provided by (Responsible Party):
Sanofi

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Primary Objective:

To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS

Secondary Objective:

To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate pharmacodynamics (PD) of SAR442168


Condition or disease Intervention/treatment Phase
Relapsing Multiple Sclerosis Drug: Tolebrutinib Drug: Teriflunomide HMR1726 Drug: Placebo to match Tolebrutinib Drug: Placebo to match Teriflunomide Phase 3

Detailed Description:
Study duration will vary per participant in this event driven trial with a treatment duration of approximately 18 to 36 months. Participants completing the study will be offered to participate in a long term safety study.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Actual Study Start Date : June 11, 2020
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: SAR442168
Dose 1 of oral SAR442168 daily + placebo to match the teriflunomide tablet once daily
 Drug: Tolebrutinib

Pharmaceutical form: Tablet

Route of administration: Oral

Other Name: SAR442168

Drug: Placebo to match Teriflunomide

Pharmaceutical form: Tablet

Route of administration: Oral
Active Comparator: Teriflunomide
Oral 14 mg oral teriflunomide + placebo to match the SAR442168 tablet once daily
 Drug: Teriflunomide HMR1726

Pharmaceutical form: Tablet

Route of administration: Oral


Drug: Placebo to match Tolebrutinib

Pharmaceutical form: Tablet

Route of administration: Oral


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Annualized Adjudicated Relapse Rate : Number of confirmed protocol defined adjudicated relapses [ Time Frame: Up to approximately 36 months ]
    Annualized Adjudicated Relapse Rate : Number of confirmed protocol defined adjudicated relapses


Secondary Outcome Measures :
  1. Time to onset of confirmed disability worsening confirmed over at least 6 months [ Time Frame: Up to approximately 36 months ]

    ime to onset of confirmed disability worsening (CDW), confirmed over at least 6 months, defined as follows:

    • increase of ≥1.5 points from the baseline expanded disability status scale (EDSS) score when the baseline score is 0 OR
    • increase of ≥1.0 point from the baseline EDSS score when the baseline score is 0.5 to ≤5.5 OR
    • increase of ≥0.5 point from the baseline EDSS score when the baseline score is >5.5 - 5.

  2. Time to onset of CDW, assessed by the EDSS score and confirmed over at least 3 months [ Time Frame: Up to 36 approximately months ]
  3. Total number of new and/or enlarging T2 hyperintense lesions as detected by MRI from Month 6 through the end of study [ Time Frame: From 6 months up to approximately 36 months ]
  4. Total Number of Gd-enhancing T1 hyperintense lesions as detected by MRI from 6 months through the End of study (EOS) [ Time Frame: From 6 months up to approximately 36 months ]
  5. Change in cognitive function [ Time Frame: From Baseline up to 36 approximately months ]
    Change in cognitive function from baseline to the EOS as assessed by the SDMT and CVLT-II where available

  6. Time to confirmed disability improvement [ Time Frame: From Baseline up to approximately 36 months ]
    Time to confirmed disability improvement (CDI), defined as a ≥1.0 point decrease on the EDSS from the baseline EDSS score confirmed over at least 6 months

  7. Percent change in Brain volume Loss as detected by brain MRI [ Time Frame: From 6 months up to approximately 36 months ]
    Brain volume loss (BVL) rate as detected by brain MRI from Month 6 to the EOS

  8. Change in Multiple Sclerosis Quality of Life-54 (MSQoL-54) [ Time Frame: From Baseline up to approximately 36 months ]
    Change in Multiple Sclerosis Quality of Life-54 (MSQoL-54) from the baseline through the EOS

  9. Number of participants with adverse events A(Es) leading to permanent study intervention discontinuation, and adverse events of special interest (AESI) [ Time Frame: From screening until end of study approximately 36 months ]
  10. Change in plasma neurofilament light chain (NfL) [ Time Frame: From Baseline until end of study up to approximately 36 months - ]
    Change in plasma neurofilament light chain (NfL) levels at the EOS compared to baselineC

  11. Changes in plasma Immunoglobulin level [ Time Frame: From Baseline until end of study up to 36 approximately months ]
    Changes in serum immunoglobulin level at the EOS compared to baseline

  12. Change in serum chitinase-3 like protein 1 (Chi3L1) - [ Time Frame: From Baseline until end of study up to approximately 36 months - ]
    Change in serum Chi3L1 levels at the EOS compared to baseline -


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • The participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent
  • The participant must have been diagnosed with RMS according to the 2017 revision of the McDonald diagnostic criteria
  • The participant has an expanded disability status scale (EDSS) score ≤5.5 at the first Screening Visit

  • The participant must have at least 1 of the following prior to screening:

    • ≥1 documented relapse within the previous year OR
    • ≥2 documented relapses within the previous 2 years, OR
    • ≥1 documented Gd enhancing lesion on an MRI scan within the previous year
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

  • Male participants are eligible to participate if they agree to the following during the intervention period and until accelerated elimination procedure:

    • Refrain from donating sperm

Plus either:

  • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
  • Must agree to use contraception/barrier as detailed below

  • Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant

    - A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions apply:

  • Is not a WOCBP OR

  • Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency during the intervention period and until accelerated elimination procedure is completed (or for at least 10 days after the last dose of SAR442168, if the case was unblinded) and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during the study and for the same period of time.

    • A WOCBP must have a negative highly sensitive pregnancy test at screening and within 24hours before the first dose of study intervention.
    • If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    • The participant must have given written informed consent prior to undertaking any study related procedure. This includes consent to comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. In countries where the legal age of maturity is greater than 18 years, a specific ICF for such legally minor participants must also be signed by the participant's legally authorized representative

Exclusion criteria:

  • The participant has been diagnosed with primary progressive multiplesclerosis (PPMS) according to the 2017 revision of the McDonald diagnostic criteria or with nonrelapsing secondary progressive multiplesclerosis (SPMS)
  • The participant has a history of infection or may be at risk for infection including but not limited to: HIV, transplantation, live attenuated vaccines, progressive multifocal leukoencephalopathy, tuberculosis, hepatitis B or C, any persistent chronic or active recurring infection
  • Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at Screening.

  • The participant has conditions or situations that would adversely affect participation in this study, including but not limited to:

    • A short life expectancy due to pre-existing health condition(s) as determined by their treating neurologist
    • Medical condition(s) or concomitant disease(s) making them nonevaluable for the primary efficacy endpoint or that would adversely affect participation in this study, as judged by the Investigator
    • A requirement for concomitant treatment that could bias the primary evaluation
  • The participant has a history of or currently has concomitant medical or clinical conditions that would adversely affect participation in this study
  • At screening, the participant is positive for hepatitis B surface antigen and/or hepatitis B core antibody and/or is positive for hepatitis C antibody

  • The participant has any of the following:

    • A bleeding disorder or known platelet dysfunction at any time prior to the screening visit
    • A platelet count <150 000/μL at the screening visit
  • The participant has a lymphocyte count below the lower limit of normal (LLN) at the screening visit
  • The presence of psychiatric disturbance or substance abuse
  • Prior/concomitant therapy
  • The participant is receiving potent and moderate inducers of cytochrome P450 (CYP) 3A or potent inhibitors of CYP2C8 hepatic enzymes
  • The participant is receiving anticoagulant/antiplatelet therapies
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04410991


Locations
Show Show 185 study locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT04410991    
Other Study ID Numbers: EFC16034
U1111-1238-1373 ( Other Identifier: UTN )
First Posted: June 1, 2020    Key Record Dates
Last Update Posted: August 8, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Teriflunomide
 Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Immunosuppressive Agents
Immunologic Factors